Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 1 diabetes is a disease where the beta cells have been destroyed so that little or no insulin is made. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to restore the ability to produce insulin in type 1 diabetic patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
63
1.5 mL, once daily, self-administered SC injection for 90 days
1.5 mL, once daily, self-administered SC injection for 90 days
1.5 mL, once daily, self-administered SC injection for 90 days
Radiant Research
Irvine, California, United States
VA Hospital UCSD
San Diego, California, United States
Diablo Clinical Research
Walnut Creek, California, United States
assess efficacy and safety based on arginine stimulated C peptide, fasting C peptide, average daily insulin dose, fasting glucose, glycosylated hemoglobin (Hb A1c), and AEs
Time frame: 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
MedStar Clinical Research Center
Washington D.C., District of Columbia, United States
Springfield Diabetes and Endocrine Center
Springfield, Illinois, United States
Mercury Street Medical
Butte, Montana, United States
UNC Diabetes Care Center
Durham, North Carolina, United States
Clinical Research Institute of Southern Oregon
Medford, Oregon, United States
University of Texas Health Science Center - Texas Diabetes Institute
San Antonio, Texas, United States
DGD Research Associates
San Antonio, Texas, United States